Please sign in to follow a disease.
Could a brazilian superfruit ease kidney disease complications?
NCT ID NCT06394531
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether a supplement made from jaboticaba peel can reduce inflammation, oxidative stress, and gut bacteria imbalances in people with chronic kidney disease. Thirty adults will take either the jaboticaba extract or a placebo for one month. Researchers will measure changes in blood and stool samples to see if the supplement has any beneficial effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Jaboticaba peel extract (a dietary supplement rich in phenolic compounds)
- What this could lead to
- If it works, this could point toward a simple, natural supplement to help manage inflammation and gut health in people with chronic kidney disease.
- What could go wrong
- This is a very small, early-stage trial with only 30 participants. The supplement may show no benefit, and results may not apply to all kidney disease patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 75 years * Clinical diagnosis of Chronic Kidney Disease * Conservative treatment group: CKD stages 3 and 5 receiving nutritional treatment for at least 6 months * Hemodialysis group: Hemodialysis patients for more than 6 months Exclusion Criteria: * Patients pregnant * Smokers * Using antibiotics in the last 3 months * Autoimmune diseases * Clinical diagnosis of infectious diseases * Clinical diagnosis of Cancer * Clinical diagnosis of AIDS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Denise Mafra
Rio de Janeiro, Rio de Janeiro, 22260050, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Does better dialysis keep parathyroid hormone in check?
- Biobank aims to unlock the mysteries of calciphylaxis
- Do kidney patients know why a fistula matters before dialysis?
- Potassium binder may let kidney patients keep Life-Saving heart drugs